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thrombosis/bleeding were not significantly different between
the randomized groups.
Two of the strongest baseline determinants of infarct size
are: 1) anterior MI location and 2) abnormal TIMI flow. This
trial was limited to patients with proximal or mid LAD
occlusion and TIMI 0e2 flow. Moreover, it only enrolled
patients who could be treated early, in whom timewindow for
effective myocardial salvage had not closed. The median time
from symptom onset to hospital arrival was only 99 min and
the median D-to-B time was 45 min. Thus the study pop-
ulation represents a highly selected cohort of patients with
large anterior MI, in whom infarct size reduction should be
feasible given early presentation and rapid treatment. Infarct
size was assessed by cMRI, which strongly correlates with
subsequent mortality. Unlike prior studies, which measured
infarct size at 2e7 days (a period during which substantial
myocardial edema is present, thereby interfering with
assessment of viable myocardium) in this study cMRI was
done at 30 days when much of myocardial edema had
resolved.
These results need to be placed in the context of previous
studies. A meta-analysis of 6 RCT’s (1246 patients) reported
enhanced survival with bolus intracoronary abciximab.
However, the recent AIDA-STEMI trial (2065 patients) found
nearly identical rates of MACE with bolus intracoronary and
intravenous abciximab. However, this trial differs from these
earlier studies in many ways: 1) unlike prior studies which
included routine post-PCI intravenous abciximab infusion in
both the groups, in this trial only bolus intracoronary abcix-
imabwas given in the randomized groups. 2) In all prior trials
(including AIDA-STEMI), intracoronary abciximabwas infused
proximally through the guide catheter thereby limiting its
penetration into occlusive thrombus and allowing spillage of
the drug to LCx or backflow into the aorta. In contrast, the
local drug delivery catheter (clearway catheter) used in this
study achieves high intra-clot concentration of abciximab at
the site of LAD occlusion and prolongs drug residence time,
which may enhance platelet disaggregation and thrombus
resolution. In the present study, an abciximab bolus delivered
directly to the infarct lesion site (without a 12-hour infusion)
reduced infarct size at 30 days in patients with anterior STEMI
reperfused early.
Regarding aspiration thrombectomy, in TAPAS, 1071
patients with anterior and non-anterior STEMI who presented
within 12 h of symptoms at a single-center were randomized
to manual aspiration vs. no aspiration before primary PCI;
aspiration resulted in modest improvements in MBG and STR
but a marked reduction in 1-year mortality. Other trials have
reported conflicting results, and in contrast to single-center
studies, multicenter aspiration trials have been largely neg-
ative. Moreover, in TAPAS, aspiration did not reduce infarct
size as measured by cardiac biomarkers, calling into question
the mechanism underlying the survival benefit. The present
multicenter trial, in which only patients presenting early with
anteriorMI and coronary anatomy optimal for aspirationwere
enrolled, and in which cMRI was used to assess infarct size at
30 days was specifically designed to overcome many of the
limitations from these earlier studies. The fact that manual
thrombus aspiration did not reduce infarct size in this studymakes a substantial clinical benefit unlikely, questioning its
routine use in STEMI.
9. Our opinion
Regarding use of GPIIb/IIIa inhibitors: a) I/V bolus and infusion
is to be discouraged because it achieves very little intra-clot
concentration and also increases the risk of systemic bleed-
ing. b) Only bolus intracoronary drug should be used, that too
not into the guide catheter, but via a clearway catheter (we can
use a simple PTCA balloon by making multiple holes on its
surface, in case clearway catheter is not available).
Regarding manual aspiration via Export catheter: a) the
symptom onset to hospital arrival and the D-to-B time were
substantially shorter in this study which is next to impossible
in our context. b) As time passes by after STEMI thrombus
tends to get organized and hence thrombus aspiration might
have some role to play in late presenters of STEMI. However,
the last word in this matter is yet to be written.
Suraj Khanal*
Assistant Professor of Cardiology, Department of Cardiology,
3rd Floor, Block-C, Advanced Cardiac Center, PGIMER,
Chandigarh 160012, India
Ajay Bahl
Associate Professor of Cardiology, PGIMER, Chandigarh, India
*Corresponding author. Tel.: þ91 09878222526.
E-mail address: khanal.s@rediffmail.comAzeem Latib, Antonio Colombo, Fausto Castriota,Antonio Micari, Alberto Cremonesi, Francesco De Felice,
Alfredo Marchese, Maurizio Tespili, Patrizia Presbitero,
Gregory A. Sgueglia, Francesca Buffoli, Corrado Tamburino,
Ferdinando Varbella, Alberto Menozzi, A randomized multi-
centre study comparing a paclitaxel drug-eluting balloonwith
a paclitaxel-eluting stent in small coronary vessels: The
BELLO (Balloon Elution and Late Loss Optimization) study. J
Am Coll Cardiol. 60 (2012) 2473e2480
Objectives: The aim of this study was to evaluate the effi-
cacy of drug-eluting balloons (DEB) compared with paclitaxel
eluting stents (PES) for the reduction of restenosis in small
vessels.
Background: DEB have been shown to be effective in the
treatment of coronary in-stent restenosis, but data are limited
regarding their efficacy in de-novo disease.
Methods:BELLO (BalloonElution and Late LossOptimization)
is a prospective, multicentre trial that randomized 182 patients
with lesions located in small vessels (reference diameter
<2.8 mm) to treatment with paclitaxel DEB and provisional
bare-metal stenting (n ¼ 90) or PES implantation (n ¼ 92). The
primary endpoint was noninferiority of angiographic in-stent
(in-balloon) late loss with a delta of 0.25 mm. Secondary end-
points were angiographic restenosis, target lesion revasculari-
zation, and major adverse cardiac events (MACE; death, myo-
cardial infarction, target vessel revascularization) at 6 months.
Results: Baseline characteristics were well matched,
except for a smaller vessel size in the DEB group
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8 221(2.15  0.27 mm vs. 2.25  0.24 mm; p ¼ 0.003). The majority
(89%) of lesions involved vessels with a diameter<2.5 mm.
Bailout stenting was required in 20% of lesions in the DEB
group. The primary endpoint of in-stent (in-balloon) late loss
was significantly less with DEB compared with PES
(0.08  0.38 mm vs. 0.29  0.44 mm; difference 0.21; 95% CI:
0.34 to 0.09; p noninferiority < 0.001; p superiority ¼ 0.001).
At 6 months, DEB and PES were associated with similar rates
of angiographic restenosis (8.9% vs. 14.1%; p ¼ 0.25), target
lesion revascularization (4.4% vs. 7.6%; p ¼ 0.37), and MACE
(7.8% vs. 13.2%; p ¼ 0.77).
Conclusions: Treatment of small-vessel disease with a
paclitaxel DEB was associated with less angiographic late loss
and similar rates of restenosis and revascularization as a PES.
1. Perspective
Themain findings of the BELLO trial are: in patientswith small
vessel CAD, the IN.PACT Falcon paclitaxel-coated DEB is non-
inferior to PES (Taxus Liberte) in suppressing neointimal
proliferation as measured by angiographic late loss at 6
months. Also the rates of MACE, MI and TLR were similar
between the two groups. However, these results were
obtained with the need to implant BMS in 20% of patients
randomized to DEB. Though the validity of late loss as a pri-
mary endpoint may be questioned; two recent trials (one in
patients with ISR and the other in AMI patients) had used this
as an endpoint. Despite the suboptimal acute angiographic
result as measured by final MLD and acute gain, DEB was
associated with similar end-points at 6 months as PES. This is
probably explained by the fact that the lower acute gain with
DEBwas counterbalanced by the very low late loss resulting in
a net lumen gain, which was comparable in both groups.
DEB can provide a therapeutic option in very small vessels
(<2.25 mm), which comprised more than half of the lesions
treated in this study, for which DES sizes are not available.
Till the results of the BELLO trial were out, limited data
was available regarding DEB in de-novo small-vessel disease.
The only other published study, PICCOLETO was a small
single-center trial that randomized 60 patients with small-
vessel disease (2.75 mm) to the Dior paclitaxel-coated bal-
loon or PES. This trial was stopped prematurely because of
the clear superiority of PES both in terms of angiographic
restenosis and MACE. Although the Dior and IN.PACT Falcon
DEB are both coated with paclitaxel at 3 mg/mm2, these
technologies are not comparable and differ significantly in
regards to balloon technology, drug-coating process, exci-
pient used as drug carrier and transport facilitator to the
vessel wall. As has been demonstrated with DES platforms,
clinical outcomes may be very different, despite elution of
the same drug. The only other DEB data available on small
vessel disease is the PEPCAD-I SVD study. In this pro-
spective, nonrandomized multicentre study, 122 patients
with CAD in 2.25e2.8 mm diameter vessels were treated with
SeQuent Please paclitaxel-coated DEB. This study demon-
strated a higher late loss in lesions treated with a combi-
nation of DEB and BMS, especially if geographic mismatch
occurred (i.e., stent implanted in an area that was not trea-
ted with DEB). In the BELLO study, this geographic mismatch
has been carefully avoided, which might explain the lowerlate loss rates even when a BMS was needed to be used. The
lower late loss in patients treated only with DEB in the
present study can also be explained by the fact that less
complex lesions were selected, where the possibility of
requirement of additional stenting was low. It is also
important to note that patients treated with DEB alone did
not experience any thrombotic event, acute vessel closure or
higher rate of periprocedural MI.
In my opinion, after the results of BELLO trial, DEB can be
used as an adjunctive tool but not as a substitute to DES. In
addition to its proven role in in-stent restenosis, DEB can be
used in circumstances in which the operator may not be fully
confident to deploy a DES such as in the treatment of lesions
in very small vessels (<2.25mmdiameter) as DES is available
only upto 2.25 mm. Till now we do not have any treatment
strategy for such vessels which can be an important diagonal,
obtuse marginal, PDA or PLV branches. Also it can be thought
of as a strategy in very long lesions to avoid the excessive
number of DES that may be required. However, till such time
that larger studies with hard clinical end-points become
available, it would not be wise to use DEB in lesions of
2.5 mm diameter as DES are available for these sizes and
with newer generation DES available, the restenosis rates and
MACE are also much lower.
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Background: To assess the proportion and long-term
outcomes of patients with idiopathic dilated cardiomyop-
athy and potential indications for implantable cardioverter-
defibrillator before and after optimization of medical
treatment, 503 consecutive patients with idiopathic dilated
cardiomyopathy were evaluated from 1988 to 2006.
Results: A total of 245 patients (49%) satisfied the
“Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
criteria,” defined as a left ventricular ejection fraction of
<0.35 and New York Heart Association (NYHA) class IIeIII
on registration. Among these, 162 (group A) were re-
evaluated 5.4  2 months later with concurrent beta
blockers and angiotensin-converting enzyme inhibitor use.
Of the 162 patients, 50 (31%) still had “SCD-HeFT criteria”
(group A1), 109 (67%) had an improved left ventricular
ejection fraction and/or New York Heart Association class
(group A2), and 3 (2%) were in NYHA class IV. Of the 227
